Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
100 participants
INTERVENTIONAL
2015-01-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications .
However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries.
Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
NCT06315478
Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males
NCT06509139
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
NCT02422706
Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children
NCT04415983
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)
NCT05997433
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Unfortunately, the most frequently used "rescue" or "salvage" therapy is bismuth quadruple therapy consisting of a proton pump inhibitor (PPI), tetracycline, metronidazole, and bismuth \[11\]. This rescue therapy is inexpensive, and relatively effective with average eradication rate of 70% when used as second-line therapy. However, disadvantages of bismuth based quadruple therapy include the large daily number of pills (sometimes exceeding 18 pills), increased dosing frequency (four times daily), and frequent side effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quadruple therapy
Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
Nitazoxanide
Nitazoxanide 500 mg twice daily
Levofloxacin
Levofloxacin 500 mg once daily
Doxycyclin
Doxycyclin 100 mg twice daily
Omeprazole
Omeprazole 40 mg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nitazoxanide
Nitazoxanide 500 mg twice daily
Levofloxacin
Levofloxacin 500 mg once daily
Doxycyclin
Doxycyclin 100 mg twice daily
Omeprazole
Omeprazole 40 mg twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in whom the standard triple therapy (clarithromycin-based triple therapy) failed
Exclusion Criteria
* Those with co-existing serious illnesses such as liver cirrhosis, uremia and gastrointestinal malignancies
* pregnancy/lactation
* having contraindication or allergy to any of the study drugs
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Hepatology and Gastroenterology Dept., Tanta university, M.D., Principle investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherief Abd-Elsalam, lecturer
Role: PRINCIPAL_INVESTIGATOR
Tropical medicine-Tanta university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tropical medicine dept.-Tanta university hospital
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Quadruple therapy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.